The Apex Times
Above the Noise
Business Wire
BusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex Times
Back to front
Eli Lilly brings oral weight-loss and type 2 diabetes drug Foundayo to the UK, first European commercial rollout
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 24, 7:47 AM EDT

Eli Lilly brings oral weight-loss and type 2 diabetes drug Foundayo to the UK, first European commercial rollout

The company said Foundayo, an oral treatment targeting weight management and type 2 diabetes, is now commercially available in the UK, making Britain the first European market where the drug can be prescribed.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Eli Lilly is starting sales in the UK for Foundayo, an oral medicine the company positions for both weight management and the treatment of type 2 diabetes. In a market update carried by Yahoo Finance, Lilly said the launch makes the UK the first European market where Foundayo is commercially available.

The announcement is notable because it expands access for a drug class that has been dominated in recent years by injectable therapies aimed at weight reduction and glycemic control. Lilly’s move also underscores the competitive push among major drugmakers to broaden convenient dosing options beyond injections, particularly as demand rises for effective, longer-term weight and metabolic care.

Foundayo is described by Lilly as a single oral treatment addressing two related clinical goals. That dual positioning matters for payer decisions and prescribing patterns, because it frames the product not only as a weight-loss option but also as part of a diabetes treatment pathway for patients with type 2 diabetes.

By naming the UK as the first European commercial market, Lilly implicitly sets a stepwise expansion plan for Europe. The company did not, in the post carried by Yahoo Finance, provide a timetable for other European countries or clarify what stage of regulatory or commercial readiness applies elsewhere on the continent.

The update does not include details on pricing, formulary coverage, reimbursement terms, or expected prescribing uptake in the UK. It also does not break out which Lilly affiliates will handle distribution there, or whether the launch is limited to specific patient subgroups.

Industry observers typically watch launches like this for indicates about how quickly oral metabolic therapies can move through health systems that may require prior authorization, specialty prescribing, or defined clinical criteria. Those mechanics can materially affect near-term revenue even when regulatory availability is in place.

For investors and competitors, the UK launch is also a reference point for future competitive positioning in Europe. It comes at a time when weight management is a central focus area for large pharmaceutical companies, and convenience, tolerability, and long-term adherence are increasingly part of how products are differentiated.

Lilly did not disclose, in the post summarized in the market item, any new UK-specific clinical data, launch volume targets, or guidance for future sales. What is clear from the announcement is the immediate geographic milestone and the company’s intent to establish Foundayo commercially ahead of broader European rollouts.

Why It Matters

  • A first European commercial rollout can accelerate demand for Lilly’s oral option and shape early market share in the region.
  • If payers and clinicians respond favorably, an oral therapy could change prescribing patterns and patient access compared with injectable alternatives.
  • The launch highlights Europe’s role as a key competitive battleground for weight and metabolic drugs, not just the US.
  • The absence of disclosed pricing and coverage details leaves uncertainty around near-term commercial impact in the UK.

Sources

Key Facts

  • Eli Lilly said Foundayo is now commercially available in the UK.
  • Lilly described Foundayo as an oral treatment for weight management and type 2 diabetes.
  • The company said the UK is the first European market where Foundayo is commercially available.
  • The announcement did not provide pricing, reimbursement, or coverage details for the UK.
  • The post did not specify launch timing for other European countries.

Healthcare Related

Eli Lilly brings oral weight-loss and type 2 diabetes drug Foundayo to the UK, first European commercial rollout | The Apex Times